Screener
Viridian Therapeutics, Inc. VRDN Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -569.7%+121,261pp | -543.9%+111,047pp | -512.9%+98,506pp | -463.5%+93,259pp | -121,831.1%-34,753pp | |
| Net margin | -544.1%+112,263pp | -508.5%+101,584pp | -483.6%+88,904pp | -426.6%+84,701pp | -112,806.9%-33,621pp | |
| Returns | ||||||
| Return on equity | -65.7%+0.1pp | -58.1%-6.2pp | -49.2%-0.7pp | -49.9%+2.0pp | -65.9%-11.9pp | |
| Return on invested capital | -78.5%+7.4pp | -76.5%-10.7pp | -64.8%-0.9pp | -73.9%+4.2pp | -85.9%-12.1pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×+0.1× | 0.1×+0.1× | 0.1×+0.1× | 0.1×+0.1× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 16.9×+5.9× | 15.1×-4.3× | 12.6×-2.8× | 11.3×-7.3× | 11×-4.8× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×+0.1× | 0.1×0.0× | 0.1×0.0× | 0×0.0× | 0×0.0× | |
| Valuation | ||||||
| Market capitalization | $2.55B+81.7% | $2B+82.0% | $2.97B+95.6% | $1.76B+1.4% | $1.2B+44.1% | |
| Price / sales | 35.9×-4,565× | 28.2×-3,609× | 41.9×-4,986× | 24.9×-5,727× | 3,921.8×+1,039× | |
| Price / book | 3.9×+1.1× | 3.1×+1.3× | 4.1×+1.9× | 3.5×+1.0× | 2.3×+0.8× |
FAQ
- What are Viridian Therapeutics, Inc.'s profit margins?
- Viridian Therapeutics, Inc. (VRDN) runs a 36.3% gross margin and a -569.7% operating margin, with a -544.1% net margin.
- Where do Viridian Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Viridian Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
